Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 11/05/2012 - 8:57am.

  2. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Adverse effects of azacitidine: onset, duration, and treatment

    ... with survivals of close to only 1 year. The use of azacitidine , a DNA methyltransferase inhibitor, in this group of patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... Azacitidine is now considered one of the standard-of-care agents for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... retrospective cohort of 282 higher-risk MDS treated with azacitidine , including 32 patients who concomitantly received an ESA for a median of 5.8months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached ...

    Research Article last updated 07/28/2014 - 9:30am.

  6. Top expert calls future MDS/AML care “promising”

    ... agents, such as SGI-110 (guadecitabine) or CC-486 (oral azacitidine ). What are the ongoing clinical trials in this space? ...

    Article last updated 11/02/2016 - 11:28am.

  7. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes

    ... that alter the natural history of the disease. Azacitidine is the only drug reported to improve overall survival in higher ...

    Research Article last updated 09/19/2016 - 11:11am.

  8. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... Azacitidine treatment is effective in higher risk MDS (HR-MDS), with less ...

    Research Article last updated 09/13/2016 - 2:47pm.

  9. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

    Journal Title:  Leukemia Primary Author:  Dinmohamed AG Author(s):  Dinmohame...

    Research Article last updated 10/12/2015 - 10:22am.

  10. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... Abstract The hypomethylating agents azacitidine and decitabine are standard therapy for ... who were treated with decitabine after primary or secondary azacitidine failure at the University of Maryland Greenebaum Cancer Center. ...

    Research Article last updated 10/02/2014 - 10:13am.